MINRAD International, Inc. Announces FDA Approval of Sojourn(TM) Sevoflurane
02 Mayo 2007 - 4:30PM
PR Newswire (US)
ORCHARD PARK, N.Y., May 2 /PRNewswire-FirstCall/ -- MINRAD
International, Inc. today announced it has received approval from
the U.S. Food and Drug Administration to market Sojourn(TM)
(Sevoflurane) inhalation anesthetic. Contact: Timothy Sheehan, VP -
Corporate Development (716) 855-1068 http://www.minrad.com/ About
the Company MINRAD International, Inc. is an interventional pain
management company with real-time image guidance and anesthesia and
analgesia product lines. The real-time image guidance products
facilitate minimally invasive surgery especially for pain
management and have broad applications in orthopedics,
neurosurgery, and interventional radiology. These devices enable
medical professionals to improve the accuracy of interventional
procedures and reduce radiation exposure. MINRAD International also
manufactures and markets generic inhalation anesthetics for use in
connection with human and veterinary surgical procedures. The
company is developing a drug/drug delivery system for conscious
sedation, which, similar to nitrous oxide in dental surgery,
provides a patient with pain relief without loss of consciousness.
Additional information can be found at the company's website,
http://www.minrad.com/. The information contained in this news
release, other than historical information, consists of
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. These statements may
involve risks and uncertainties that could cause actual results to
differ materially from those described in such statements. Factors
that may cause actual results to differ materially from those
expressed or implied by its forward-looking statements include, but
are not limited to, MINRAD International's limited operating
history and business development associated with being a growth
stage company; its dependence on key personnel; its need to attract
and retain technical and managerial personnel; its ability to
execute its business strategy; the intense competition it faces;
its ability to protect its intellectual property and proprietary
technologies; its exposure to product liability claims resulting
from the use of its products; general economic and capital market
conditions; financial conditions of its customers and their
perception of its financial condition relative to that of its
competitors; as well as those risks described under the heading
"Risk Factors" of MINRAD International's Form 10-KSB, filed with
the Securities and Exchange Commission on March 29, 2006. Although
MINRAD International, Inc. believes that the expectations reflected
in such forward-looking statements are reasonable, it can give no
assurance that such expectations will prove to have been correct.
DATASOURCE: MINRAD International, Inc. CONTACT: Timothy Sheehan, VP
- Corporate Development of MINRAD International, Inc.,
+1-716-855-1068, or Web site: http://www.minrad.com/
Copyright